Table 2.
35 enriched pathways at FDR < 0.1 in at least one group of MDD patients as compared to controls in enrichment analyses of inflammatory pathways
| P value | |||
|---|---|---|---|
| Pathway | All MDD | MDD with hyperphagia | MDD with hypophagia |
| KEGG natural killer cell mediated cytotoxicity | 7.94E-6 | 5.20E-4 | 0.0138 |
| KEGG T cell receptor signaling | 1.39E-4 | 2.09E-3 | 0.0411 |
| PID IL-8 CXCR2 | 1.39E-4 | 2.94E-3 | 5.79E-4 |
| Reactome adaptive immune system | 3.70E-4 | 4.25E-3 | 4.98E-4 |
| Reactome immune system | 5.60E-4 | 2.07E-3 | 3.98E-3 |
| PID IL-8 CXCR1 | 5.71E-4 | 6.19E-3 | 2.32E-3 |
| Reactome signaling by interleukins | 6.93E-4 | 1.22E-3 | 0.0344 |
| PID CXCR4 pathway | 1.41E-3 | 4.80E-3 | 7.66E-3 |
| Reactome IL-3, IL-5 and GM-CSF signaling | 2.80E-3 | 4.70E-4 | 8.10E-3 |
| Reactome apoptosis | 4.85E-3 | 0.0147 | 0.0101 |
| Reactome inflammasomes | 6.08E-3 | 1.71E-3 | 0.149 |
| BioCarta natural killer cells pathway | 2.62E-3 | 0.0637 | 4.17E-3 |
| PID aMb2 neutrophils pathway | 7.69E-3 | 0.0230 | 9.63E-3 |
| PID CD8 TCR downstream pathway | 8.42E-3 | 0.0283 | 0.0380 |
| PID caspase pathway | 0.0188 | 3.76E-4 | 0.0558 |
| BioCarta GATA3 pathway | 0.0280 | 4.10E-4 | 0.0359 |
| PID NFAT transcription factor pathway | 0.0297 | 5.10E-4 | 0.154 |
| BioCarta PAR1 pathway | 0.203 | 1.73E-3 | 0.127 |
| Reactome the NLRP3 inflammasome | 0.0101 | 3.06E-3 | 0.0240 |
| BioCarta IL22BP pathway | 0.0749 | 4.11E-3 | 7.54E-3 |
| KEGG apoptosis | 0.0452 | 5.10E-3 | 0.169 |
| PID IL-4 2pathway | 0.474 | 5.48E-3 | 0.170 |
| ST interleukin 4 pathway | 0.110 | 5.67E-3 | 0.0101 |
| Reactome IL-6 signaling | 0.143 | 6.13E-3 | 0.107 |
| PID angiopoietin receptor pathway | 0.0136 | 6.29E-3 | 0.0284 |
| Reactome nucleotide-binding domain leucine-rich repeat containing receptor NLR signaling pathways | 0.0520 | 7.73E-3 | 0.161 |
| Reactome cytokine signaling in immune system | 0.0129 | 8.36E-3 | 0.128 |
| BioCarta IL2RB pathway | 0.123 | 0.0125 | 0.208 |
| BioCarta mitochondria pathway | 0.303 | 0.0155 | 0.224 |
| BioCarta IL-6 pathway | 0.497 | 0.0162 | 0.182 |
| BioCarta TNFR1 pathway | 0.389 | 0.0167 | 0.403 |
| KEGG JAK-STAT signaling pathway | 0.173 | 0.0173 | 0.322 |
| Reactome extrinsic pathway for apoptosis | 0.0147 | 0.0174 | 0.308 |
| PID IL-2 STAT5 pathway | 0.137 | 0.0181 | 0.180 |
| PID IL-12 2pathway | 0.0206 | 0.0190 | 0.0372 |
The values represent the raw P values obtained from the enrichment analyses. Bold values correspond to an FDR < 0.1
The raw P values and corresponding FDRs of the enrichment analyses of all 162 inflammatory pathways are listed in Supplementary Table 5. Supplementary Table 6 presents, of the 25% percentile genes with the lowest P value within each pathway, the percentage of genes with a positive effect size in the differential gene expression analysis
CD cluster of differentiation, CXCR chemokine receptor, GM-CSF granulocyte-macrophage colony-stimulating factor, IL interleukin, IL22BP interleukin-22 binding protein, IL2RB interleukin-2 receptor beta subunit, JAK Janus Kinase, KEGG Kyoto Encyclopedia of Genes and Genomes, NFAT nuclear factor of activated T cells, NLR nucleotide-binding domain leucine-rich repeat, NLRP3 nucleotide-binding domain leucine-rich repeat containing family pyrin domain-containing-3, PAR1 protease-activated receptors, ST signaling transduction KE, STAT signal transducer and activator of transcription, TCR T cell receptor, TNFR1 tumor necrosis factor receptor 1